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ABSTRACT
Globalization of markets and production networks has made it
progressively harder for low income countries to industrialize.
This article addresses a conundrum facing industrial firms and
industrial policy in a low-income African country: how to
achieve upgrading necessary for sustained competitiveness.
Using data from a study of manufacturers of health products in
Tanzania, we document the double ‘squeeze’ on firms’ profits
exerted by sharp price competition alongside competitive
pressure for rising product quality within globalized markets.
Drawing on Sutton’s model of competing on capabilities, and
the sectoral systems of innovation and production framework,
we argue that ‘dynamic industrial deepening’, strengthening
domestic inter-firm linkages, is a key requirement for sustainable
development of these health industries. We present evidence
that sectoral industrial support for the health industries can
promote sustainable technological upgrading, and reflect on the
challenge of building developmental linkages where external








The rise of East and South Asian manufactured exports, alongside global trade liberaliza-
tion and the integration of global manufacturing networks, has made it increasingly hard
for low income countries (LICs) to follow in emerging industrializers’ footsteps, with
Sub-Saharan Africa (SSA) facing particularly severe challenges (Sutton 2012; Newman
et al. 2016). In this article, we analyse responses to this challenge from Tanzania’s
health industries, that is, manufacturers of pharmaceuticals and other health essentials.
Manufacturers in health industries are important components of health innovation
systems as they contribute to the creation and diffusion of new products and technologies
through market and non-market linkages to a variety of private and public organizations
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(Natera, Tomassini, and Vera-Cruz 2019). Urias (2019) showed that competitive health
industries, nurtured by appropriate industrial policy, can contribute to health policy and
promote access to medicines.
Adopting an innovation system perspective, we investigate the following questions:
what were the upgrading challenges and responses of manufacturers in Tanzania’s
health industries in the period 2012–2017? Are there any useful lessons for policy
aimed at strengthening health industries in LICs facing international competition?
We show that, as Sutton (2012) indicated, all firms interviewed were trying to adapt to
international competitive pressure through industrial upgrading, that is, by innovating to
reduce costs by improving production processes, raise the quality of existing products
and expand the product range to include more technologically complex product (Pietro-
belli and Rabellotti 2006). We identify a key actual and potential route to sustaining com-
petitiveness in the process of dynamic industrial deepening. Industrial deepening can be
defined as ‘the formation of local linkages and the creation of a robust local supplier base’
(Kuroiwa 2015, 1), whilst the term dynamic indicates the centrality of learning to develop
skills, knowledge, experience and adapted institutional linkages to generate and manage
technical change throughout the supply chain.
We then explore how sectoral industrial support for the health industries can promote
sustainable technological upgrading within locally owned business structures typical of
LICs, and the scope for building domestic developmental industrial linkages as external
investment required for major upgrading transforms those business structures. Having
gained the status of lower-middle income country in 2020, at the time of the research
Tanzania was a low-income economy which had undergone fluctuating economic for-
tunes and industrial policy regimes since Independence in 1960, including protected
industrialization with price controls, import substitution, macroeconomic liberalization
with export promotion and, most recently, openness coupled with newly active industrial
policy (Wangwe 1995; Msami and Wangwe 2016; McMillan, Page, and Wangwe 2017).
Pharmaceutical manufacturing has mirrored these fluctuations, and faced a sharp decline
in the period from 2009 to 2013. The market share of local producers fell from 35% to
under 20%, and a deteriorating international trade balance saw a fall in exports from
US$8 million in 2009 to US$1.7 million in 2013 and a sharp rise in imports to US$286
million, over half of it from India (Tibandebage et al. 2016; URT 2016; Wande et al.
2019).
This article presents evidence of the upgrading challenges (Section 3), and employs a
framework drawn from the Sutton’s (2007, 2012) model of competing on capabilities,
and the sectoral systems of innovation and production framework (Malerba 2002;
Malerba and Mani 2009), to demonstrate the importance of dynamic industrial deepen-
ing for sustained competitiveness, and the evolving constraints within current business
structures (Sections 5-8). The discussion (Section 9) draws out industrial policy oppor-
tunities that may have wider resonance in LICs.
2. Sources and methods
Evidence is drawn from analysis of interviews in Tanzania in 2012/2013 with multiple
interviewees in the five main pharmaceutical firms producing human medicines at
that date, and in six manufacturers of other health supplies such as specialized furniture,
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hygiene and cleaning items, and packaging materials. Semi-structured interviews covered
business history, strategy and constraints; production organization and technological
level; and domestic and export market access. Eleven further interviews included
public and private wholesalers, regulators and government officials, and a manufacturing
association. The interviews formed part of a broader project on health-industry linkages
in Tanzania and Kenya1 that also included quantitative and qualitative health sector
supply chain research (Mackintosh et al. 2016, 2018).
In 2017, follow-up interviews in Tanzania2 were conducted with two pharmaceutical
manufacturers and a new industrial investor; the public wholesaler; government officials
responsible for regulation and policy making; and a pharmaceutical training institution.
East African community officials and senior Global Fund managers were interviewed
about pharmaceutical production and procurement in the region.
Data from the Learning to Compete (L2C)3 2012 survey in Tanzania are used here for
context and framing. Qualitative responses in the survey were coded to assist analysis.
Useable responses were received from 49 firms, of which 14 were in sectors relevant to
this article, including five firms interviewed for this study.
Ethical clearance was obtained from the Open University Human Research Ethics
Committee in the UK (HREC/2011/#956/2), and the National Institute for Medical
Research, Ethics Review Committee in Tanzania. All participants had consented to the
research, having been assured that participation was voluntary and that their anonymity
would be preserved in published research findings.
3. Analytical framework: capability development within a sectoral system
of innovation and production
Sutton’s (2007, 2012) model of the impact of globalized industrial competition on devel-
oping countries’ manufacturing offers a useful framework to analyse the challenges and
responses of business in the Tanzanian health industries. In Sutton’s model, consumers
will pay a premium for quality, and markets display a moving ‘capability window’ charac-
terized by a rising quality/cost threshold below which firms will be unable to sell. Firms
with capabilities that enable them to successfully distinguish themselves for high quality
cannot be driven out of a market by firms selling cheap but low-quality products. Hence,
low labour costs can compensate for low productivity but not for low quality.
Firms in LICs facing global import competition after market liberalization must there-
fore invest in learning to build their capabilities, in order to stay in business and compete
with firms from high capabilities countries as quality thresholds rise. Sutton recognizes
that ‘the determinants of the speed and effectiveness of this process [of capability build-
ing]… are only partially understood’ (Sutton 2007, F471).
This study addresses this research gap for one LIC by drawing on the work of Malerba
(2002) on sectoral systems of innovation and production (SSIP). An SSIP approach
focusses on the key actors, networks, institutions and processes that drive innovative
activity in a sector. It is intended as ‘not a straitjacket, but a broad, flexible and adaptable
tool. It points to some key variables and fundamental relationships. Only the goals of the
analysis will decide which levels of aggregation should be used, depending on the purpose
of the analysis’ (Malerba and Mani 2009, 4).
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The firms interviewed are heterogeneous, including higher-skilled pharmaceuticals
manufacturing alongside some of the ‘light manufacturing’ often promoted for African
industrial policy support (Dinh et al. 2012), and fall into different industrial sectors (as
defined by standard industrial classifications). Nevertheless, the health industry
businesses, as a sector, share common features that influence the ability of firms to
upgrade: the nature of competition, driven by a rising price/quality threshold as
described in Sutton’s model; an institutional environment characterized by rising regu-
latory standards for health industries and tariff-induced cost disadvantage for local firms;
a shallow industrial structure with significant gaps in supply chains; weak labour and
financial markets with scarcity of skilled workers and finance that is limited and expens-
ive; and market demand shaped by international philanthropic procurement, domestic
wholesalers (public, faith-based, private), and low-income out-of-pocket purchasing,
with strong exposure to international price competition.
In the evolutionary economics literature that underpins the SSIP framework, firms are
key agents which, through learning, accumulate distinctive capabilities that enable them
to upgrade by introducing new products and processes (Bell and Pavitt 1993). However,
firms do not operate in a vacuum: they rely instead on a network of market and non-
market relationships with suppliers, users, government agencies, labour and financial
institutions and other organizations in order to accumulate their capabilities. Lall
(1992) emphasized the importance of linkage capabilities, which are ‘the skills needed
to transmit information, skills and technology to, and receive them from, component
or raw material suppliers, subcontractors, consultants, service firms, and technology
institutions’ (Lall 1992, 168), alongside production capabilities needed to successfully
run and improve industrial processes, and investment capabilities needed to successfully
expand production and set up new facilities.
Input-output relationships with buyers and with suppliers of inputs are the key lin-
kages in the Tanzanian health industries innovation system. The process of upgrading
through learning and the accumulation of capabilities within health industries, including
strengthening of domestic industrial linkages over time, we call ‘dynamic industrial dee-
pening’. Dynamic industrial deepening refers to the development of a broad-based, resi-
lient supply chain in which participants adapt and learn to develop new technological
and linkage capabilities. Learning to generate and manage technical change, with its
associated skills, knowledge, experience and adapted institutional linkages, is necessary
to be competitive in a highly dynamic market environment characterized by rising
price-quality thresholds over time.
4. The challenge of the price-quality squeeze arising from international
competition
In line with the scenario analysed in Sutton’s model, over the period of this research, the
health industries in Tanzania, pharmaceutical and other suppliers, were facing a severe
competitive ‘squeeze’ between intensifying price competition from imports, and com-
petitive pressure to invest to upgrade. Price competition in pharmaceuticals had inten-
sified after 2009 when tariffs on finished formulations fell to zero. That policy,
advocated by the WHO and international NGOs, aimed to reduce domestic medicines
prices, an objective confirmed by Tanzanian tax authorities interviewed in 2014. Other
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imports for health care such as hospital beds were also exempt from duty. However par-
allel removal of tariffs on imported inputs for domestic manufacturing, such as active
pharmaceutical ingredients (APIs), had faced difficulties where inputs had wider use,
such as highly refined sugar for pharmaceutical syrups or inputs for furniture production
that could also be used for household goods. Domestic manufacturers therefore faced
tariff-induced cost disadvantage against importers of finished essential health
commodities.
All firms interviewed also reported continual pressure to meet rising quality standards
by introducing improved and new products, which in turn require better industrial pro-
cesses and improved organizational capabilities. The products of the health industries are
necessarily highly regulated for quality, in terms of safety and efficacy. The Tanzanian
Food and Drug Authority (TFDA, now the TMDA4), widely seen as one of the strongest
African regulators, supports and requires local manufacturers to upgrade their pro-
duction processes to Good Manufacturing Practice (GMP) standards. International
donors, who set the procurement terms for funded HIV, TB and anti-malarial medi-
cation, require the more stringent WHO-prequalification certification for each pharma-
ceutical product, or approval by a stringent regulator such as USFDA. Quality, in the
sense of documented meeting of regulatory quality and safety standards, is therefore
an important aspect of competitive advantage in the health industries because it is key
to market access. The manufacturers interviewed stated that external pressure for
rising standards was also driven by quality-based external competition; by new data
on dangers e.g. from cross-contamination; by rising regulatory standards in high
income countries (HICs), and also incentives for established multinational exporters
to raise quality-based barriers to entry. All the firms’ business responses to the ‘double
squeeze’ of intensifying price competition and rising quality assurance market entry bar-
riers were upgrading- and quality-focused.
Similarly, firms interviewed for the L2C data set prioritized competitive upgrading
within business strategies. Asked for four key success elements for the company, 62%
identified product quality as key to success, a much larger proportion than any other
single element, such as labour availability and skills (25%); customers and marketing
(20%), and management competences (33%). These findings echo Sutton’s (2012, 54)
comment that ‘quality is a constantly recurring theme’ in conversations with Indian
and Chinese manufacturers, productivity (unit labour cost) less so.
5. Business structure as strength and constraint
Firms are the key actors in a sectoral innovation system. Firms under competitive
pressure must build capabilities to innovate and upgrade within their current business
structures, or adapt those structures to enhance learning. The firms interviewed in Tan-
zania in 2013 and 2017 were business survivors and successful adaptors to extremely
challenging business conditions. Some had survived the rapid import liberalization of
the 1980s and early 1990s, which had wiped out much of manufacturing (Wangwe
1995); others had restarted or established from the late 1990s.
All firms grappled with poor and expensive infrastructure, as in many LICs: poor
quality water, intermittent electricity, and poor road, rail and port infrastructure
subject to institutionalized delays (Andreoni 2017; Sutton and Olomi 2012; Lall and
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Wangwe 1997). In the L2C sample, 88% of firms, and 100% of chemical (including
pharmaceutical), plastics and textile firms said they ‘often’ experienced insufficient elec-
tricity supply. Although recently the reliability of electricity supply has significantly
improved, two thirds of firms interviewed in 2013 identified expensive and intermittent
mains electricity as a major constraint and cost driver; the plastics, pharmaceutical and
textile firms all required expensive power generation backup and machine protection.
The shallow industrial structure that emerged in Tanzania from the 1980s crisis and
the loss of trade barriers (Wangwe 1995) was also beset by institutional voids, including
scarce and expensive loan capital, shortages of skilled labour, and supply chain gaps
resulting from weak or absent local suppliers of key inputs. Responding to these circum-
stances, businesses interviewed were mainly family firms, or businesses within diversified
family owned conglomerates or business groups (Table 1). These large business groups
dominate Tanzanian manufacturing, often having roots in East African trading activities;
many are in East African Asian ownership (Sutton and Olomi 2012).
All had begun in family ownership except one pharmaceutical producer, set up
initially as a state-owned enterprise which collapsed in the crisis years then was reopened
as public-private joint ventures in 1995 by Tanzanian African family business owners. A
large producer of long-lasting insecticidal bed nets (LLINs) was structured as a joint
venture between a Japanese multinational and a Tanzanian partner which, in turn,
was part of a family owned diversified textiles and plastics group. All other suppliers
were family businesses of various sizes, ranging from small enterprises to a large
family conglomerate (Table 1).
This business structure has strengths and weaknesses as part of a sectoral innovation
system. Competitive advantages include the ability to move funds internally to econom-
ize on loan capital, and share skilled people within the group (Khannah and Yafeh 2007).
Internal diversification spreads risk in uncertain market, contracting and political con-
texts (Carney 2007), and can fill supply chain gaps e.g. by building in-house logistics.
Global reach helps business groups to control quality of inputs and reduce search and
contracting costs, and can facilitate technology transfer in contexts with poor market
intelligence (Sutton and Olomi 2012). However, family owners may also be risk-
averse, undermining innovation by focusing on preserving family wealth (Carney
2007). Fears of loss of control may block external equity investment and cause resistance
to managerial changes needed for growth in technologically complex industries.


















Hygiene items 1 1
Bed nets 1 1
Total 12 9 1 2
Note: *Local = Tanzanian, Kenyan or DRC ownership **MNC: Multinational corporation.
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It is therefore notable that the exceptions to pure family ownership were in the tech-
nologically more complex fields of pharmaceuticals and long-lasting insecticide-treated
bed nets (LLINs) (Table 1). Furthermore, by 2017, this pattern had been reinforced.
The largest pharmaceutical firm in Tanzania had moved from joint local /overseas own-
ership to 100% ownership by Aspen, a South Africa-based multinational. Another
pharmaceutical firm had been sold by family owners in 2016 to a Kenya-based private
equity fund. As shown below, scope for innovation and upgrading was thereby strength-
ened (see also Portelli and Narula 2006).
6. Industrial deepening: local supplier networks as key for sustaining
competitiveness
Robust supply chains with good quality relationships between suppliers and users are
an important element of successful SSIPs. However, Tanzania’s shallow manufactur-
ing sector has few firms in each sub-sector, limiting the development of labour pools,
narrowing markets, and creating large gaps in competencies and input suppliers. As
Table 2 shows, the firms interviewed were strongly reliant on imported inputs
including core intermediate items, and they identified this dependence on inter-
national supply chains as a sharp constraint on cost control and quality assurance.
Pharmaceutical firms, for example, faced overseas exporters of finished formulations
some of whom had the competitive advantage of vertical integration with API
suppliers.
Table 2 suggests scope for strengthening local upstream supply chains in Tanzania,
since many inputs from textiles and cotton to packaging could potentially be supplied
locally without major technological upgrading. Other inputs however, such as APIs
and polymer, would require a much larger jump in national technological level e.g. in
chemicals.
Table 2. Country sources of main intermediate inputs, machinery and technology.
Main products Country sources of main inputs
Country sources of machinery and
technology
Pharmaceuticals APIs: India and China.
Starch, sugar, packaging, bottles: India and
China.
Secondary packaging, pyrethrum: Tanzania.
Incidental inputs, packaging: Kenya.
Mainly India, some China. Older
equipment Germany and UK.
Plastic goods Polymer: India, China, Malaysia, Korea. Injection machinery: Canada, Japan.
Furniture Steel pipes, steel and metal parts, paint, plastic,
textiles, packaging: Tanzania.
Sheet steel: import (unspecified).
Powder for coating: Dubai.
India. Some old UK equipment
Mattresses Polyurethane, PVC fabric for mattresses: Korea:
Other fabric: India




Recycled plastic, timber, packaging, low grade




Bed nets Polymer and insecticide: Japan, Thailand Machinery: China; insecticide
proprietary technology: Japan.
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Most of the health suppliers interviewed considered the local production of inputs an
important strategy for cost control. Initiatives aiming to upgrade local suppliers in order
to loosen bottlenecks and bridge gaps in local supply chains (Simonetti, Wuyts, and
Fivawo-Wuyts 2007) are therefore important to strengthen health industries. The inter-
views identified ways in which industrial deepening through extending backward lin-
kages had been used, or potentially could be used, to strengthen local supply chains
and improve manufacturing competitiveness for the individual firms and the sector.
Table 3 reports the challenges and potential and actual solutions in upgrading local sup-
pliers and sourcing domestic inputs.
The following example of potential mutual benefit between local suppliers blocked by
a contracting dilemma illustrates both a characteristic problem in shallow markets, and
the scope for facilitative intervention. Local pharmaceutical firms produced bottled
syrups for children’s medication, such as antibiotic syrups. Production processes for
the bottles must therefore meet pharmaceutical quality standards such as air handling
and cleanliness. In 2013, pharmaceutical manufacturers imported glass bottles for this
purpose from India. However, glass bottles are heavy, fragile and, inefficient to transport.
So why not use plastic bottles made locally?
A plastics firm stated that they had the capability and technology to produce plastic
bottles for this purpose. However to do so required substantial upgrading of the existing
Table 3. Upgrading challenges and potential solutions: strengthening supply chains.
Products Capability upgrading challenges Main constraints Actual and potential solutions
Plastics Technological capability to
produce bottles to higher
pharmaceutical standards




Agreed longer contracts from
buyers and government de-
risking /guarantees to make
investment viable






Public sector support for upgrading
through enforcement of quality
standards in tenders and longer
contracts to support investment
Furniture Technological capability to work
with stainless steel.
High cost of upgrade to
handle stainless steel.
Public sector support for upgrading
through enforcement of quality
standards in tenders and longer
contracts to support investment
Cleaning
equipment
Cost cutting by switching to
local recycled plastic
Low quality of local
recycled plastic
suppliers.
Buying contracts with quality
specification and support to
suppliers
Public support for local recycling
industry: technology, supplies,
upgrading.
Pharmaceuticals Cost cutting by switching from
glass to plastic bottles and
greater automation




contracting with local suppliers
Pharmaceuticals Continuing move to blisters
packaging; improved










In-house upgrading and long-term
contracting with local suppliers;
in-house and loan finance
Bed nets Logistics for cost-effective




In-house logistics: lower cost and
reliability in delivery.
Mattresses Improved foaming equipment Skill levels of production
employees
Public investment in vocational
training
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plastics plant, since at the time the plant was producing, for pharmaceuticals, only exter-
nal packaging for bulk tablets already plastic-packed in the pharmaceutical plant, not
requiring them to meet pharmaceutical primary packaging standards. The upgrading
installation would make commercial sense only if the plastics firm had a long enough
supply contract from a pharmaceutical firm to ensure a return on the investment.
Conversely, a pharmaceutical firm pointed out that they would need to invest in new
equipment to handle the plastic bottles, without a guarantee of the quality of the locally
produced bottles. Because of quality doubts, they would not give a contract in advance to
the plastics firm, so continued to use imported glass bottles.
This dilemma is generated by the small number of both local buyers (pharma-
ceutical firms producing syrups) and local producers (plastics firms with the capability
to produce the bottles). Demand and supply sides are ‘shallow’, so for each firm to
move first risked finding themselves with a product with no buyer / a production
line with no local supplier. The mutual dilemma has the form of an ‘assurance
game’: the two firms are stuck in a low-level equilibrium trap. Both prefer a higher-
level equilibrium where both invest. But they cannot reach their preferred position
because of lack of assurance about how the other will respond. Scope for intervention
to resolve the dilemma is discussed below.
Conversely however, a brush and cleaning equipment supplier of health facilities
had earlier managed to overcome directly a comparable supply chain problem
through collaboration between firms to upgrade a local supplier. Faced with severe
Chinese price-based import competition in its domestic market, the local firm had
fought back with cost cutting and quality improvement. The key to business survival,
according to the firm’s owner, had been a switch from imported plastic to locally
recycled plastic for brush handles. The cleaning products firm had worked with a
local plastics recycler to sharply improve the recycler’s product quality to their
specified level. They had then given the recycler a large supply contract, and the
switch had sharply reduced costs. The firm had also learned from competitors and
trade fairs to develop a more attractive, better coloured product range. The firm’s
large market share was retained, and the quality of local recycled plastic on the
market rose. The firm was stimulating further improvements in local recycled
plastic, to further reduce costs.
In some cases, firms managed to compensate for the lack of local suppliers by
developing alternative in-house solutions. Two furniture makers interviewed mostly
used local recycled steel. They both faced severe lower-price, lower-quality compe-
tition from China and India, in public tenders to supply hospital and health
center furniture, and also quality-based competition from imports using stainless
steel. As it could not fund the upgraded machinery needed to handle stainless
steel, one of the firms responded by improving powder coating technology and
strengthening other aspects of quality including durability and appropriate product
design such as mechanical bed adjustment not reliant on – always intermittent –
power supplies.
Conversely, a high-volume producer of long-lasting insecticide-treated bed nets had
responded to problems with local logistics firms by building up an in-house logistics
arm to achieve more reliable and lower cost East African regional distribution: an
example of internal vertical integration to deal with a lack of industrial depth.
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Problems with local inputs could also sink local manufacturers. A previously suc-
cessful manufacturer of hygiene products never recovered after it lost its cheap
supply of raw cotton from waste of local weaving firms when the Tanzanian textile
industry largely collapsed. More expensive, poorer quality cotton wool undermined
market access.
7. Sustaining technology access and upgrading over time: international
networks
For incremental upgrades, developing local suppliers and relying on internal resources
within diversified business groups remained effective. Many firms interviewed had
funded these repeated upgrading investments from other family businesses. Finance
for incremental upgrading was not seen as their central investment problem, and the
L2C survey data supports this finding.
Malerba and Mani recognize that ‘the dimensions of sectoral systems are not
necessarily national’ (2009, 3). The health industries, for example, have an important
international dimension in access to technology. To keep up to date, and import
improved technology efficiently, global linkage capabilities were key to business survi-
val and development. In the diversified family businesses, these networks were fre-
quently internal to the group, and supplemented by industrial fairs and associated
networking. Two pharmaceutical firms were within East African Asian business
groups with associated enterprises in India. Technology access challenges included
equipment purchase, for process upgrading or new product mixes, and also
ongoing maintenance, repair and adaptation, for which staff training was key.
Working relationships with external suppliers of technology were frequently long
term, supporting both maintenance and upgrading. Equipment supply packages
characteristically included machinery installation, skills transfer and training,
financial support for technology purchase, spare part supply and maintenance, and
ongoing organizational advice.
Most firms interviewed were using Indian or Chinese machinery (Table 2) mainly
for cost reasons. Indian and Chinese suppliers installed machinery and trained oper-
ators, while after-sales service was described as reasonable, though spare parts could
take 2–3 weeks. The use of Chinese and Indian equipment, as elsewhere in the
region, had lowered barriers to entry to manufacturing, with lower cost if less
robust equipment (Hanlin and Kaplinsky 2016), However, Germany, Italy and
Japan had responded to Chinese and Indian competition by developing lower cost
packages adapted to lower income markets. In one case, a German company had
put together a competitive technologically ‘stripped-down’ equipment package, plus
a training presence locally for six months to a year. The local firm stated this was
slightly more expensive than Chinese competitors’ offers, but was believed to be a
more robust product: ‘we are thinking medium term’.
Building long-term external supplier relationships was a key linkage capability for
development in a context with low local technological industrial capability. A firm
using German suppliers since the 1960s received parts ‘on the basis of trust’, not
waiting for pre-payment, and received training in new technology by sending the son
of the owner to work at the German supplier’s plant.
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Developing new linkage capabilities through international trade fairs was also impor-
tant to source new technology. A processor of recycled plastic found an Italian supplier
which arranged installation, training, and parts supply, and was considering US technol-
ogy embodied in Taiwanese-made injection moulding machinery for a future
investment.
8. Upgrading capabilities to meet globalizing market challenges:
requirements for a technological ‘leap’
While much of the upgrading described so far could be done incrementally, and largely
with internal business finance, four of the larger higher technology firms, the three largest
pharmaceutical firms and the firm producing insecticide-treated bed nets, faced a greater
upgrading challenge in responding to the double squeeze.
The demand for their products was increasingly dominated by external donor funding
and associated stringent and rising regulatory standards. In pharmaceuticals, expanded
funding for anti-malarial, HIV and TB medication had become dominated by inter-
national tenders (Mackintosh et al. 2018). The bed nets firm stated that their market
was almost entirely donor-funded through international tendering, and they had
achieved the WHO prequalification required for market entry. International price com-
petition in bed nets tenders was described as ‘cut-throat’. The pharmaceutical firms had
been losing domestic market share because of inability to meet WHO prequalification
and because of large scale and price-based competition in the tender markets. The
pharmaceutical firms reported increasing price competition from imports with some evi-
dence of dumping of antibiotics from India at around local API import costs and adverse
institutional changes, such as the loss of tariff protection on health products in 2009.
This severe double squeeze led to the closure of product lines. The largest pharma-
ceutical firm by 2014 had closed its entire antibiotic output including children’s antibiotic
syrups and also dropped many other low-margin basics such as mebendazole. They were
aiming to move into more complex higher-margin formulations including combination
tablets, and new branded basics such as oral rehydration salts with zinc. A second firm
continued to run its penicillins plant selling at cost, to ‘use the assets’, but they would
consider closing the lines if they lost money. This CEO argued that 10% tariff protection
on final products would have been sufficient to sustain profitability.
These larger firms, in pharmaceuticals and textiles, needed to increase their product
quality and range, improved processes and invest in new plant and equipment to serve
their globalizing markets more competitively. They needed major technology upgrades
which required more complex investment capabilities, including sourcing and licensing
new technology, procuring equipment, automating processes, training and recruitment
of skilled personnel and carry out some research and development (Lall 1992) (Table 4).
In pharmaceuticals, the process innovations required to cut costs and expand product
range included moving into higher value products. The required capabilities included
identifying, funding, accessing, installing and using improved technology effectively;
improving plant, production machinery, air and waste handling and laboratory equip-
ment; finding or training more skilled labour; and sharply improving process documen-
tation. The bed nets firm was exploring new uses for its netting technology.
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In each case, a major leap in capabilities required firms to link technology transfer to
substantial associated funding. The interlinked needs for technology and finance reveal
the constraints on radical upgrading from the previous local business group structure,
loosened by changing ownership structures. Three of these four firms had turned to over-
seas partners and changed their business structure to facilitate this leap; the fourth was
struggling to find an appropriate partner.
The largest pharmaceutical firm had been bought out by Aspen, one of the largest
global generics multinationals, in 2017. The acquisition enabled the Tanzanian subsidiary
to access technology from elsewhere in the group. Local formulation and development
(F&D) for a new product, for example, could take two years, whereas they could start
the production and licensing processes immediately. They also gained access to R&D,
auditing of suppliers of inputs such as APIs with regulatory paperwork ready for national
authorities, and investment in automation in processing and packaging while reducing
labour force numbers to cut costs.
A second pharmaceutical firm funded installation of new machinery partly with in-
house funding, but largely through a grant associated with technology transfer by an
international PPP. This firm was then bought by an East African private equity fund
whose vision was to develop a regional group of pharmaceutical companies that could
gain economies of scale e.g. through pooled API purchasing. Joint ventures were a
further way to link technology transfer to finance. The bed nets firm’s joint venture struc-
ture, between an established local textile company and a Japanese MNC had brought the
Table 4. Upgrading challenges and potential solutions: investment in complex technology.
Products Capability upgrading challenges Main constraints Actual and potential solutions
Bed nets Acquire technological
capabilities to produce long-
lasting insecticidal nets (LLIN)
with WHO pre-qualification.
Break dependence on one
donor-dominated market
through application of net




produce LLIN inputs and
funding.
Need for R&D for alternative
markets entry.
MNC partner with insecticide
and spinning technology.
MNC and other support for
local R&D for net quality and
new market applications
Bed nets Gain a price premium from




Revised donor tendering rules.






Access to technology for new
higher quality products; cost
of machinery and plant
upgrades; staff and
technology for new plant;
new production culture.
External finance and partners:
buyout by MNC with access
to in-house technology;
support from global PPP;
private equity investors;
joint ventures.
Pharmaceuticals Better process technologies: e.g.
air handling, reduced dust
levels, and economies of scale
(longer runs; higher levels of
automation)
Investment finance for
upgrading plants; skills and
technology to install and
operate a new plant; new
production culture.








skills and culture; hiring and
training; production culture;






Pharmaceuticals Improving marketing and brand
recognition
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insecticide technology to the new plant, alongside the quality control system that was the
basis for WHO prequalification, while the local firm brought the spinning and weaving
experience, and also built up the logistics for a regional distribution operation.
The changes in ownership structure also helped improve organizational culture.
Upgrading is a learning process, not only in equipment and skills improvement, but
also in adapting firms’ routines to create a culture of quality and upgrading in order
to improve processes, documentation, product quality and product range. By 2017,
one of the larger pharmaceutical firms had instituted extensive upgrading of quality
control and quality assurance systems, aiming to change the ‘temperament’ of the
factory. Another CEO commented that the firm would benefit strongly from being
able to send supervisory staff to work in a GMP environment for a period, to learn by
experience what GMP involved.
The third pharmaceutical firm, which had failed to find a new investor, was conversely
struggling to fund investment in higher value products and upgraded machinery. The
firm was also constrained in its efforts to increase capacity utilization by a lack of avail-
able skilled and supervisory staff to manage increased shifts per day to deliver a large
public contract.
There is however a danger, as firms move into ownership by or joint ventures with
MNCs, that they become more detached from local industrial linkages, increasingly
relying on overseas’ partners supply chains and services, rather than stimulating dom-
estic innovation and industrial deepening.
9. Concluding discussion: developing and sustaining industrial upgrading
in LIC health industries
The evidence presented shows that, in facing the double squeeze of rising quality and
decreasing price, the firms in the Tanzanian health industries have substantial entrepre-
neurial and organizational capabilities but also face significant challenges consistent
across the sector. There are feasible ‘policy levers’ that could help LIC firms to build com-
petitive capabilities for survival in liberalized markets. We draw three key policy-relevant
conclusions from our findings.
First, to support sustained learning and upgrading in the health industries, it is
imperative to develop sector-specific policies that address the specific weaknesses of
the SSIP. On the demand side, given the importance of the quality and price barriers
to accessing donor-funded tenders, procurement design is a key tool for governments
and donors to support market access and incentivise upgrading and industrial entry
(Chataway et al. 2016). Both the bed nets and the furniture producers commented that
donors’ quality specifications in tenders could operate as a ceiling as well as a floor on
quality, disincentivising improvement. The bed nets firm had developed the capability
to produce longer lasting nets than specified, but would then lose tenders on price. Simi-
larly, a furniture firm stated that local tendering favoured lower quality, lower price
imports, with buyers not willing to pay a premium for e.g. durability. Firms will not
be incentivised to upgrade if quality premiums are not paid in practice.
Institutional design can also contribute to the development of the sector, for example
by eliminating the tariff-induced competitive disadvantage that actively disadvantages
local manufacturers and introducing selective protection of imports to incentivise
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sectoral investment in this ‘infant industry’. Incentives and support may include a quite
low but stable level of industrial protection for final goods, to guard against dumping and
to partially compensate for local infrastructural failures (Section 5) that need medium
and long term amelioration, while incentivising continuing local supply of e.g. basic
essential medicines (Tibandebage et al. 2016). Import duties can be designed to encou-
rage equipment upgrade.
The second conclusion is the importance of supporting and incentivising dynamic
industrial deepening. The findings in Section 6 make a case for strategic sectoral inter-
vention to strengthen and deepen local supply chains and to break supply chain bottle-
necks. Increased access to good quality local inputs would support cost-effective quality
improvement, and offers the potential for combining cost reduction with process and
product improvements, for example by targeted support for upgrading in the large
and competitive local recycling industry or in sectors such as card- and plastic -based
packaging, where local suppliers could feasibly replace imports. Business services, includ-
ing IT, technology services and equipment maintenance are other domestic input sectors
whose support would strengthen local supply chains. More ambitiously, Tanzania could
invest in R&D to enhance input supplies to pharmaceuticals, for example by developing
and producing local excipients, as is being tried in Ethiopia (Gebre-Mariam, Tahir, and
Gebre-Amanual 2016).
Skills policies are also needed, to support both the health industries and their upstream
suppliers, by filling skills gaps such as industrial pharmacists and industrial laboratory
technicians.
Capability building takes time, so procurement, sectoral support and skills building all
require a long-term perspective, to generate cumulative sectoral improvement. That
longer term contracts in procurement can incentivise investment and linkage develop-
ment is now recognized by the main health procurement body in Tanzania (Mackintosh
et al. 2017) and could be expanded further. Domestic procurement rules requiring
increased local content over time could provide an incentive to invest within supply
chains, and could help to break the kind of ‘assurance’ dilemma described in Section
6. Donors too could seek to bridge upstream supply chain gaps, for example through
value chain lending of the type practised within the agricultural sector (Simonetti,
Wuyts, and Fivawo-Wuyts 2007). These approaches require a shift in national procure-
ment thinking, away from automatic recourse to international tenders, toward a mix that
includes active support for capability building in local ‘lead firms’ (Sutton 2014), combin-
ing funding, contracts and advice to support firms’ development. Among large inter-
national actors such as the Global Fund, a shift to more developmental procurement
thinking is visible, for example, using concepts of ‘total landed cost’ to recognize the
benefits of suppliers’ proximity, and avoiding winner-takes-all tendering frameworks
(Mackintosh et al. 2017).
Third, upgrading to access new markets, and to lower costs through a jump to much
larger scale, can require a change in business structure to access the combination of tech-
nology, learning and finance required for the jump (Section 8). Several firms had
achieved major upgrades through international MNC buyout, joint venture development
or international PPP support. When tackling international tender markets, active gov-
ernment support can help an ambitious local firm to gain important first-mover advan-
tages. The bed nets producer, for example, gained WHO-prequalification early in the
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development of the donor-dominated market for long lasting insecticide-impregnated
nets. Winning an initial large tender, with allowance for rapid depreciation of the
initial investment, made the firm more competitive over time as more competitors
came in. Capable firms can be assisted to climb market-access barriers early through
active support to upgrade to meet market entry barriers, e.g. support for focused skill
development, or linking local firms to technology institutes and universities. Location
in export processing zones can also be helpful in these circumstances.
Policy levers could further influence both choice of institutional route and the impact
on industrial deepening. Joint ventures, where a local partner is an active player, may be
better placed to generate local linkages that a 100% MNC buyout which may produce a
more ‘enclave’ company relying largely on external linkages within the parent MNC.
Governments can shape joint venture development, through information, business
development guidance, and by actively hosting meetings to encourage and support
local suppliers. Government can also identify, for potential donor-support, investments
seen as locally strategic, and encourage greater transfer of technological and organiz-
ational capability over time to both lead companies and upstream suppliers. Regulatory
bodies such as the TFDA (now TMDA) already provide advice for upgrading, and could
perhaps play a more active role in generating external support.
Finally, one of the attractions for policy makers of a focus on dynamic industrial dee-
pening is its support for broader development agendas. Local production of essential
medical supplies is increasingly seen by African governments as a strategic security
concern (Mackintosh et al. 2017; URT 2016; EAC 2017) justifying active government
intervention, a focus strengthened by the coronavirus pandemic. The strengthening of
upstream linkages, for example in packaging and recycled plastics, also has positive
spill-over effects for firms in other sectors using these inputs.
The concept of dynamic industrial deepening, introduced and developed in this
article, thus has intellectual parallels with a strand of the economic development litera-
ture rooted in work by Hirschman’s that is increasingly revisited (Hirschman 1977; Sai-
Wing Ho 2019). Hirschman defined linkages as ‘investment-generating forces that are set
in motion, through input-output relations, when productive facilities that supply inputs
to that line or utilize its outputs are inadequate or non-existent’ (Hirschman 1977, 72).
His ‘generalised linkage approach’ to economic development was therefore inherently
dynamic, since ‘linkages effects need time to unfold’ (Hirschman 1977, 70–71). Srinivas
(2016) further notes that Hirschman’s policy approach, arising from the focus on linkage
development, was one of problem-solving to support developmental investment. Sutton
(2014:, 1) makes a closely related point in arguing for the policy importance of a Local
Content Unit to generate linkages to primary production in Tanzania, with the
purpose of expanding and deepening the domestic business sector as a spin-off from
the offshore gas industry. While most of the applications in this literature focus on creat-
ing backwards linkages from primary products, this article’s findings suggest that the fra-
mework has much wider application including in the health industries.
Notes
1. Industrial productivity, heath sector performance and policy synergies for inclusive growth:
a study in Tanzania and Kenya: see Acknowledgements.
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2. Research funded by BMZ, German Development Cooperation: see Acknowledgements.
3. Data collected in Tanzania by REPOA in 2012 by a team led by XXXX, under the UNU-
WIDER Learning to Compete project.
4. The Tanzania Medicines and Medical Devices Authority (TMDA), Executive Agency regu-
lating medicines, medical devices and diagnostics, from July 2019.
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